HCP Connect Clinical Author
Dr. Shruti Pandey
Hematology
Specialty
Hematology
Clinical Updates
18
Experience
6 Years
Author Biography
About Dr. Shruti Pandey
Dr. Shruti Pandey is a clinical haematologist with 6 years of experience. She completed a DM in Clinical Haematology following an MD in General Medicine, focusing on leukaemias and coagulation disorders. She takes keen interest in the evolving role of targeted and cellular therapies. Her writing translates haematology advances into practical clinical guidance.
Published Work
Recent Clinical Updates
18 articles
Hematology
CAR-T Therapy in DLBCL and Multiple Myeloma: Outcomes and Optimization
ciltacabtagene autoleucel multiple myeloma: deep-dive on CARTITUDE-4, real-world comparisons, and CAR-T optimization for hematologists.
Hematology
FDA Approves Acalabrutinib + Venetoclax for CLL/SLL: PFS HR 0.65 in AMPLIFY
acalabrutinib chronic lymphocytic leukemia: FDA approves acalabrutinib plus venetoclax for adults with previously untreated CLL/SLL (AMPLIFY PFS HR 0.65).
Hematology
AURORA: Bitopertin Reduced Protoporphyrin‑IX 49.8% in Erythropoietic Protoporphyria
Bitopertin erythropoietic protoporphyria: AURORA trial showed -49.8% protoporphyrin‑IX change with 60 mg vs placebo; reduced phototoxic reactions and favorable tolerability.
Hematology
narsoplimab: FDA Approves for TA-TMA; 61% TMA Response
narsoplimab TA-TMA: FDA approves Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy with 61% TMA response.
Hematology
FDA Approves Daratumumab for NDMM Ineligible for ASCT: 52.3% MRD
FDA approves daratumumab (DARZALEX FASPRO) with VRd for newly diagnosed multiple myeloma in ASCT-ineligible adults; CEPHEUS: 52.3% MRD vs 34.8%, PFS HR 0.60.
Hematology
FDA Approves Fitusiran for Hemophilia A/B: Median Treated ABR 3.7
Fitusiran (QFITLIA) approved for hemophilia A/B prophylaxis; median treated ABR 3.7 in ATLAS-OLE; antithrombin-guided dosing and safety monitoring required.
Hematology
FDA Approves imetelstat for LR-MDS: 40% 8-week RBC-TI in IMerge
Imetelstat (RYTELO) FDA approved for transfusion-dependent low‑ to intermediate‑1 risk MDS after IMerge showed 40% achieved 8‑week RBC‑TI vs 15% with placebo.
Medical Research
Novel Therapy Achieves 90% Response in Rare Sarcoma
New targeted radiation approach reduces cancer activity and provides symptom relief in patients with solitary fibrous tumors, a rare and often malignant soft tissue tumor.
Medical Research
Cut Opioid Relapse Rates with Evidence-Based Meds
Learn how primary care clinics can help curb the opioid epidemic with effective medications and overcome treatment barriers to improve patient outcomes.
Healthcare Business
Integrated Care Cuts Pediatric Behavioral Issues by 30%
Discover how integrated primary care services can improve pediatric behavioral health outcomes and reduce symptom scores in children, enhancing overall well-being and quality of li...
Medical Research
Identify Microcephaly Cause with SNW1 Gene Mutation
Discover how mutations in the SNW1 gene are linked to neurodevelopment disorders with microcephaly, informing diagnosis and treatment approaches for affected patients.
Medical Research
Uncover Root Causes of Liver Fibrosis
Discover how metabolic dysfunction and lipid accumulation contribute to liver fibrosis, and learn how to identify and manage underlying causes in your patients.
Medical Research
Uncover Microbiome's Role in RA Progression
Discover how microbiome changes impact rheumatoid arthritis treatment and patient outcomes, and what it means for your practice.
Medical Research
Reduces EPP-Related Liver Disease by Targeting Erythroid PPIX
Discover how inhibiting GLYT1 mitigates liver disease in erythroid protoporphyria, reducing phototoxicity and improving patient outcomes.
Medical Research
New Opioid 20x Stronger Than Fentanyl Fuels Overdose Crisis
A highly potent synthetic opioid is driving the overdose crisis, with potency hundreds of times stronger than morphine, posing a new threat to patient safety.
Pharmaceutical
Novel Protein Degraders May Revolutionize Immune Condition Treatment
Discover how new protein degrader drugs can improve treatment outcomes for immune conditions, with potential for enhanced efficacy and reduced side effects.
Digital Health
Boost Trial Efficiency with Data-Driven Site Selection
Discover how AI-powered site selection can streamline clinical trials, saving time and resources for sponsors and improving trial accessibility.
Health IT
Identify K 18 Small White Pill for Patient Safety
Quickly identify the K 18 small white pill to ensure patient safety and accurate medication administration in your practice.